The role of adrenal steroidogenesis in arterial hypertension

Endocrine Development

Volumn 13, Issue , 2008, Pages 133-144

  Mohaupt, M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; MINERALOCORTICOID; STEROID;

ADRENAL GLAND; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; FEMALE; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MATERNAL HYPERTENSION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; REVIEW;

ADRENAL GLANDS; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; FEMALE; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; MINERALOCORTICOIDS; PREGNANCY; STEROIDS;

EID: 48949104210     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000134830     Document Type: Review

References (74)

1. 11β). J Biol Chem 1989;264:20961-20967.
2. Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, Miura S, Ohnishi T, Ichikawa Y, Nakao K, Imura H, Ulick S, Shizuta Y: Role of steroid 11β-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992;89:1458-1462.
3. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z, Stratakis CA: Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab 1998;83:1033-1036.
4. Zhang G, Miller WL: The human genome contains only two CYP11B (P450c11) genes. J Clin Endocrinol Metab 1996;81:3254-3256.
5. Bechtel S, Belkina N, Bernhardt R: The effect of amino-acid substitutions I112P, D147E and K152N in CYP11B2 on the catalytic activities of the enzyme. Eur J Biochem 2002;269:1118-1127.
6. Portrat-Doyen S, Tourniaire J, Richard O, Mulatero P, Aupetit-Faisant B, Curnow KM, Pascoe L, Morel Y: Isolated aldosterone synthase deficiency caused by simultaneous E198D and V386A mutations in the CYP11B2 gene. J Clin Endocrinol Metab 1998;83:4156-4161.
7. Malee MP, Mellon SH: Zone-specific regulation of two messenger RNAs for P450c11 in the adrenals of pregnant and nonpregnant rats. Proc Natl Acad Sci USA 1991;88:4731-4735.
8. Kakiki M, Morohashi K, Nomura M, Omura T, Horie T: Regulation of aldosterone synthase cytochrome P450 (CYP11B2) and 118-hydroxylase cytochrome P450 (CYP11B1) expression in rat adrenal zona glomerulosa cells by low sodium diet and angiotensin II receptor antagonists. Biol Pharm Bull 1997;20:962-968.
9. LeHoux JG, Lefebvre A: Transcriptional activity of the hamster CYP11B2 promoter in NCI-H295 cells stimulated by angiotensin II, potassium, forskolin and bisindolylmaleimide. J Mol Endocrinol 1998;20:183-191.
10. Binnion PF, Davis JO, Brown TC, Olichney MJ: Mechanisms regulating aldosterone secretion during sodium depletion. Am J Physiol 1965;208:655-661.
11. McKenna TJ, Island DP, Nicholson WE, Liddle GW: Dopamine inhibits angiotensin-stimulated aldosterone biosynthesis in bovine adrenal cells. J Clin Invest 1979;64:287-291.
12. Hanke CJ, Drewett JG, Myers CR, Campbell WB: Nitric oxide inhibits aldosterone synthesis by a guanylyl cyclase-independent effect. Endocrinology 1998;139:4053-4060.
13. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP: Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev 1998;19:101-143.
14. Suzuki J, Otsuka F, Inagaki K, Takeda M, Ogura T, Makino H: Novel action of activin and bone morphogenetic protein in regulating aldosterone production by human adrenocortical cells. Endocrinology 2004;145:639-649.
15. Inagaki K, Otsuka F, Suzuki J, Kano Y, Takeda M, Miyoshi T, Otani H, Mimura Y, Ogura T, Makino H: Involvement of bone morphogenetic protein-6 in differential regulation of aldosterone production by angiotensin II and potassium in human adrenocortical cells. Endocrinology 2006;147:2681-2689.
16. Inagaki K, Otsuka F, Suzuki J, Otani H, Takeda M, Kano Y, Miyoshi T, Yamashita M, Ogura T, Makino H: Regulatory expression of bone morphogenetic protein-6 system in aldosterone production by human adrenocortical cells. Regul Pept 2007;138:133-140.
17. Vinson GP, Pudney JA, Whitehouse BJ: The mammalian adrenal circulation and the relationship between adrenal blood flow and steroidogenesis. J Endocrinol 1985;105:285-294.
18. Ansurudeen I, Kopprasch S, Ehrhart-Bornstein M, Willenberg HS, Krug AW, Funk RHW, Bornstein SR: Vascular-adrenal niche - endothelial cell-mediated sensitization of human adrenocortical cells to angiotensin II. Horm Metab Res 2006;38:476-480.
19. Ansurudeen I, Kopprasch S, Ehrhart-Bornstein M, Bornstein SR, Willenberg HS: Endothelial cell-mediated regulation of aldosterone release from human adrenocortical cells. Mol Cell Endocrinol 2007;265-266:150-156.
20. Clark BJ, Combs R: Angiotensin II and cyclic adenosine 3′,5′-monophosphate induce human steroidogenic acute regulatory protein transcription through a common steroidogenic factor-1 element. Endocrinology 1999;140:4390-4398.
21. Sugawara T, Sakuragi N, Minakami H: CREM confers cAMP responsiveness in human steroidogenic acute regulatory protein expression in NCI-H295R cells rather than SF-1/Ad4BP. J Endocrinol 2006;191:327-337.
22. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE: Primary aldosteronism and hypertensive disease. Hypertension 2003;42:161-165.
23. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M-J, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY study investigators: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006;48:2293-2300.
24. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999;353:40.
25. Calhoun DA: Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006;1:1039-1045.
26. Biglieri EG, Schambelan M: The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin Endocrinol Metab 1979;49:87-91.
27. Auchus RJ, Chandler DW, Singeetham S, Chokshi N, Nwariaku FE, Dolmatch BL, Holt SA, Wians FH Jr, Josephs SC, Trimmer CK, Lopera J, Vongpatanasin W, Nesbitt SD, Leonard D, Victor RG: Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism. J Clin Endocrinol Metab 2007;92:2648-2651.
28. Nwariaku FE, Miller BS, Auchus R, Holt S, Watumull L, Dolmatch B, Nesbitt S, Vongpatanasin W, Victor R, Wians F, Livingston E, Snyder WH: Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome. Arch Surg 2006;141:497-503.
29. Tanabe A, Naruse M, Arai K, Naruse K, Yoshimoto T, Seki T, Imaki T, Kobayashi M, Miyazaki H, Demura H: Angiotensin II stimulates both aldosterone secretion and DNA synthesis via type 1 but not type 2 receptors in bovine adrenocortical cells. J Endocrinol Invest 1998;21:668-672.
30. Schubert B, Fassnacht M, Beuschlein F, Zenkert S, Allolio B, Reincke M: Angiotensin II type 1 receptor and ACTH receptor expression in human adrenocortical neoplasms. Clin Endocrinol 2001;54:627-632.
31. Takeda Y, Usukura M, Yoneda T, Oda N, Ito Y, Mabuchi H: The expression of messenger RNA for ADP-ribosyl cyclase in aldosterone-producing adenomas. Clin Endocrinol 2005;62:504-508.
32. Wu K-D, Chen Y-M, Chu T-S, Chueh S-C, Wu M-H, Hsieh B-S: Expression and localization of human dopamine D2 and D4 receptor mRNA in the adrenal gland, aldosterone-producing adenoma, and pheochromocytoma. J Clin Endocrinol Metab 2001;86:4460-4467.
33. Chang H-W, Chu T-S, Huang H-Y, Chueh S-C, Wu V-C, Chen Y-M, Hsieh B-S, Wu K-D: Down-regulation of D2 dopamine receptor and increased protein kinase CW phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab 2007;92:1863-1870.
34. Cartier D, Jégou S, Parmentier F, Lihrmann I, Louiset E, Kuhn J-M, Bastard C, Plouin P-F, Godin M, Vaudry H, Lefebvre H: Expression profile of serotonin4 (5-HT4) receptors in adrenocortical aldosterone-producing adenomas. Eur J Endocrinol 2005;153:939-947.
35. Perraudin V, Delarue C, Lefebvre H, Do Rego J-L, Vaudry H, Kuhn J-M: Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies. J Clin Endocrinol Metab 2006;91:1566-1572.
36. Spät A, Hunyady L: Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004;84:489-539.
37. Gummow BM, Winnay JN, Hammer GD: Convergence of Wnt signaling and steroidogenic factor-1 (SF-1) on transcription of the rat inhibin gene. J Biol Chem 2003;278:26572-26579.
38. Schinner S, Willenberg HS, Krause D, Schott M, Lamounier-Zepter V, Krug AW, Ehrhart-Bornstein M, Bornstein SR, Scherbaum WA: Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes 2007;31:864-870.
39. Krug AW, Vleugels K, Schinner S, Lamounier-Zepter V, Ziegler CG, Bornstein SR, Ehrhart-Bornstein M: Human adipocytes induce an ERK1/2 MAP kinases-mediated upregulation of steroidogenic acute regulatory protein (StAR) and an angiotensin II-sensitization in human adrenocortical cells. Int J Obes 2007;31:1605-1616.
40. Inglis GC, Plouin PF, Friel EC, Davies E, Fraser R, Connell JMC: Polymorphic differences from normal in the aldosterone synthase gene (CYP11B2) in patients with primary hyperaldosteronism and adrenal tumour (Conn's syndrome). Clin Endocrinol 2001;54:725-730.
41. White PC, Slutsker L: Haplotype analysis of CYP11B2. Endocr Res 1995;21:437-442.
42. Müssig K, Wehrmann M, Horger M, Maser-Gluth C, Haring H-U, Overkamp D: Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension. J Endocrinol Invest 2005;28:61-65.
43. Griffing GT, Wilson TE, Holbrook MM, Dale SL, Jackson TK, Ullrich I, Melby JC: Plasma and urinary 19-nor-deoxycorticosterone in 17α-hydroxylase deficiency syndrome. J Clin Endocrinol Metab 1984;59:1011-1015.
44. Nicod J, Dick B, Frey FJ, Ferrari P: Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production. Mol Cell Endocrinol 2004;214:167-174.
45. Gallery EDM, Hunyor SN, Györy AZ: Plasma volume contraction: a significant factor in both pregnancy-associated hypertension (pre-eclampsia) and chronic hypertension in pregnancy. Q J Med 1979;48:593-602.
46. Spaanderman MEA, Aardenburg R, Ekhart THA, van Eyndhoven HWF, van der Heijden OWH, van Eyck J, de Leeuw PW, Peeters LLH: Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. Eur J Obstet Gynecol Reprod Biol 2001;95:218-221.
47. Gallery EDM, Brown MA: Control of sodium excretion in human pregnancy. Am J Kidney Dis 1987;9:290-295.
48. Mohaupt M: Molecular aspects of preeclampsia. Mol Aspects Med 2007;28:169-191.
49. Jensen E, Wood CE, Keller-Wood M: Chronic alterations in ovine maternal corticosteroid levels influence uterine blood flow and placental and fetal growth. Am J Physiol Regul Integr Comp Physiol 2005;288:R54-R61.
50. Robinson M: Salt in pregnancy. Lancet 1958;i:178-181.
51. Bower D: The influence of dietary salt intake on pre-eclampsia. J Obstet Gynaecol Br Commonw 1964;71:123-125.
52. Duley L, Henderson-Smart D, Meher S: Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev 2005;4:CD005548. DOI: 10.1002/14651858.
53. Salas SP, Marshall G, Gutiérrez BL, Rosso P: Time course of maternal plasma volume and hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006;47:203-208.
54. Shojaati K, Causevic M, Kadereit B, Dick B, Imobersteg J, Schneider H, Beinder E, Kashiwagi M, Frey BM, Frey FJ, Mohaupt MG: Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. Kidney Int 2004;66:2322-2328.
55. Ehrlich EN, Nolten WE, Oparil S, Lindheimer MD: Mineralocorticoids in normal pregnancy. Perspect Nephrol Hypertens 1976;5:189-201.
56. Ulick S, Wang JZ, Morton DH: The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. J Clin Endocrinol Metab 1992;74:1415-1420.
57. Zhang G, Rodriguez H, Fardella CE, Harris DA, Miller WL: Mutation T318M in the CYP11B2 gene encoding P450c11AS (aldosterone synthase) causes corticosterone methyl oxidase II deficiency. Am J Hum Genet 1995;57:1037-1043.
58. C18 gene (CYP11B2) in CMO II deficient patients. Biochem Biophys Res Commun 1992;182:974-979.
59. Pascoe L, Curnow KM, Slutsker L, Rösler A, White PC: Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA 1992;89:4996-5000.
60. Peter M, Bünger K, Drop SLS, Sippell WG: Molecular genetic study in two patients with congenital hypoaldosteronism (types I and II) in relation to previously published hormonal studies. Eur J Endocrinol 1998;139:96-100.
61. Fardella CE, Rodriguez H, Montero J, Zhang G, Vignolo P, Rojas A, Villarroel L, Miller WL: Genetic variation in P450c11AS in Chilean patients with low renin hypertension. J Clin Endocrinol Metab 1996;81:4347-4351.
62. Rösler A, White PC: Mutations in human 11β-hydroxylase genes: 11β-hydroxylase deficiency in Jews of Morocco and corticosterone methyl-oxidase II deficiency in Jews of Iran. J Steroid Biochem Mol Biol 1993;45:99-106.
63. C18 gene (CYP11B2) due to nucleotide deletion in CMO I deficient patients. Biochem Biophys Res Commun 1993;190:864-869.
64. C18). Biochem Biophys Res Commun 1997;234:382-385.
65. Peter M, Fawaz L, Drop SLS, Visser HKA, Sippell WG: Hereditary defect in biosynthesis of aldosterone: aldosterone synthase deficiency 1964-1997. J Clin Endocrinol Metab 1997;82:3525-3528.
66. Kayes-Wandover KM, Schindler REL, Taylor HC, White PC: Type 1 aldosterone synthase deficiency presenting in a middle-aged man. J Clin Endocrinol Metab 2001;86:1008-1012.
67. Ye P, Kenyon CJ, MacKenzie SM, Seckl JR, Fraser R, Connell JMC, Davies E: Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003;144:3321-3328.
68. Brochu M, Lehoux J-G, Picard S: Effects of gestation on enzymes controlling aldosterone synthesis in the rat adrenal. Endocrinology 1997;138:2354-2358.
69. Brochu M, Roy-Clavel E, Picard S, St-Louis J: In vivo regulation of enzymes controlling aldosterone synthesis in pregnant rats. Endocr Res 1998;24:575-579.
70. Broughton-Pipkin F: Risk factors for preeclampsia. N Engl J Med 2001;344:925-926.
71. Pojoga L, Gautier S, Blanc H, Guyene TT, Poirier O, Cambien F, Benetos A: Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998;11:856-860.
72. Maynard SE, Min J-Y, Merchan J, Lim K-H, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658.
73. Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I: Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006;291:R1085-R1093.
74. Farese S, Shojaati K, Kadereit B, Frey FJ, Mohaupt MG: Blood pressure reduction in pregnancy by sodium chloride. Nephrol Dial Transplant 2006;21:1984-1987.